Literature DB >> 25343114

The molecular and cellular basis of Apert syndrome.

Chao Liu1, Yazhou Cui2, Jing Luan2, Xiaoyan Zhou2, Jinxiang Han2.   

Abstract

Apert syndrome (AS) is a rare genetic and congenital disease characterized by craniosynostosis and syndactly of hands and feet. AS patients generally require lifelong management, however there are still no effective treatment methods except surgery. In recent years, research has made great progress in the pathogenesis of AS. FGFR2 mediates extracellular signals into cells and the mutations in the FGFR2 gene cause AS occurrence. Activated FGFs/FGFR2 signaling disrupt the balance of cell proliferation, differentiation and apoptosis via its downstream signal pathways. However, how the pathways transform the balance is not well understood and contradictions have occurred in different studies. In this review, we'll focus on these problems to get a better understanding of AS pathogenesis.

Entities:  

Keywords:  Apert syndrome; FGFR2 gene; pathogenesis; signal pathways

Year:  2013        PMID: 25343114      PMCID: PMC4204555          DOI: 10.5582/irdr.2013.v2.4.115

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  67 in total

1.  Apert syndrome with septum pellucidum agenesis.

Authors:  A Tiwari; A Agrawal; A Pratap; R Lakshmi; R Narad
Journal:  Singapore Med J       Date:  2007-02       Impact factor: 1.858

2.  Activity of 5-alpha-reductase and 17-beta-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris.

Authors:  D Thiboutot; H Knaggs; K Gilliland; G Lin
Journal:  Dermatology       Date:  1998       Impact factor: 5.366

3.  Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse.

Authors:  Yingli Wang; Ran Xiao; Fan Yang; Baktiar O Karim; Anthony J Iacovelli; Juanliang Cai; Charles P Lerner; Joan T Richtsmeier; Jen M Leszl; Cheryl A Hill; Kai Yu; David M Ornitz; Jennifer Elisseeff; David L Huso; Ethylin Wang Jabs
Journal:  Development       Date:  2005-06-23       Impact factor: 6.868

4.  Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis.

Authors:  J Lemonnier; E Haÿ; P Delannoy; A Lomri; D Modrowski; J Caverzasio; P J Marie
Journal:  J Bone Miner Res       Date:  2001-05       Impact factor: 6.741

5.  Apert syndrome.

Authors:  Anatoli Freiman; Oren Tessler; Benjamin Barankin
Journal:  Int J Dermatol       Date:  2006-11       Impact factor: 2.736

6.  Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.

Authors:  Yingli Wang; Miao Sun; Victoria L Uhlhorn; Xueyan Zhou; Inga Peter; Neus Martinez-Abadias; Cheryl A Hill; Christopher J Percival; Joan T Richtsmeier; David L Huso; Ethylin Wang Jabs
Journal:  BMC Dev Biol       Date:  2010-02-22       Impact factor: 1.978

7.  A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome.

Authors:  Yukiho Tanimoto; Masahiko Yokozeki; Kenji Hiura; Kazuya Matsumoto; Hideki Nakanishi; Toshio Matsumoto; Pierre J Marie; Keiji Moriyama
Journal:  J Biol Chem       Date:  2004-08-13       Impact factor: 5.157

8.  Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome.

Authors:  A O Wilkie; S F Slaney; M Oldridge; M D Poole; G J Ashworth; A D Hockley; R D Hayward; D J David; L J Pulleyn; P Rutland
Journal:  Nat Genet       Date:  1995-02       Impact factor: 38.330

9.  Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling.

Authors:  Hichem Miraoui; Karim Oudina; Hervé Petite; Yukiho Tanimoto; Keiji Moriyama; Pierre J Marie
Journal:  J Biol Chem       Date:  2008-12-30       Impact factor: 5.157

10.  FGFR2 mutation confers a less drastic gain of function in mesenchymal stem cells than in fibroblasts.

Authors:  Erika Yeh; Rodrigo Atique; Felipe A A Ishiy; Roberto Dalto Fanganiello; Nivaldo Alonso; Hamilton Matushita; Katia Maria da Rocha; Maria Rita Passos-Bueno
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

View more
  8 in total

Review 1.  Craniofacial malformations and their association with brain development: the importance of a multidisciplinary approach for treatment.

Authors:  Asher Ornoy
Journal:  Odontology       Date:  2019-06-06       Impact factor: 2.634

Review 2.  Research advances in Apert syndrome.

Authors:  Satrupa Das; Anjana Munshi
Journal:  J Oral Biol Craniofac Res       Date:  2017-05-25

3.  Apert Syndrome: Dental management considerations and objectives.

Authors:  Line Droubi; Mohannad Laflouf; Yasser Alsayed Tolibah; John C Comisi
Journal:  J Oral Biol Craniofac Res       Date:  2022-04-28

4.  Two patients with Apert syndrome with different mutations: the importance of early diagnosis.

Authors:  Esra Işık; Tahir Atik; Hüseyin Onay; Ferda Özkınay
Journal:  Turk Pediatri Ars       Date:  2017-12-01

Review 5.  Dental approach for Apert syndrome in children: a systematic review.

Authors:  A-S López-Estudillo; M-A Rosales-Bérber; S Ruiz-Rodríguez; A Pozos-Guillén; M-Á Noyola-Frías; A Garrocho-Rangel
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2017-11-01

6.  Apert Syndrome With FGFR2 758 C > G Mutation: A Chinese Case Report.

Authors:  Yahong Li; Dingyuan Ma; Yun Sun; Lulu Meng; Yanyun Wang; Tao Jiang
Journal:  Front Genet       Date:  2018-05-17       Impact factor: 4.599

7.  Clinical study and some molecular features of Mexican patients with syndromic craniosynostosis.

Authors:  Aurora Ibarra-Arce; Manuel Almaraz-Salinas; Víctor Martínez-Rosas; Gabriela Ortiz de Zárate-Alarcón; Laura Flores-Peña; Mirza Romero-Valdovinos; Angélica Olivo-Díaz
Journal:  Mol Genet Genomic Med       Date:  2020-06-08       Impact factor: 2.183

8.  A novel FGFR2 (S137W) mutation resulting in Apert syndrome: A case report.

Authors:  Qingyang Shi; Rulin Dai; Ruixue Wang; Jili Jing; Xiaowei Yu; Ruizhi Liu; Yanhong Liu
Journal:  Medicine (Baltimore)       Date:  2020-09-25       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.